Clinical trials: Histological Response
Peripheral T Cell Lymphoma
Transplantation After Complete Response In Patients With T-cell Lymphoma
Peripheral T-cell lymphoma (PTCL) encompasses a broad range of post-thymic (i.e., mature) sub-entities as defined by the 2017 WHO classification.
- Trial name
- TRANSCRIPT (NCT05444712)
- Testing
- Chemotherapy + follow up, Chemotherapy + ASCT + follow up
- Where
- 48 sites in France
- Volunteers
- 204 people
- Sponsor
- Hospices Civils de Lyon
Melanoma
Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma
This study aims to determine which of 3 drug combinations best reduces the size of tumour prior to surgery for advanced melanoma and prevents the recurrence of melanoma after surgery.
- Trial name
- Neo Trio (NCT02858921)
- Testing
- Dabrafenib, Trametinib, Pembrolizumab
- Where
- 3 sites in Australia
- Volunteers
- 60 people
- Sponsor
- Melanoma Institute Australia
Renal Cell Cancer
Prediction of Response to Kinase Inhibitors Based on Protein Phosphorylation Profiles in Tumor Tissue From Advanced Renal Cell Cancer Patients
The rapid development of agents blocking kinases has established the use of molecularly targeted therapy as the preferred treatment approach for patients with metastatic renal cell cancer (RCC).
- Trial name
- NCT02071719
- Where
- Netherlands
- Volunteers
- 6 people
- Sponsor
- M. Labots
Glioblastoma, Glioblastoma Multiforme
Advanced Perfusion MRI of Treatment Response and Progression in Glioblastoma
The primary aim of this project is to Compare new msCS and standard DSC-PWI methods in GBM patients undergoing post-operative MRI for monitoring of tumor progression.
- Trial name
- NCT02769806
- Testing
- MRI
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Wisconsin, Madison
Esophageal Squamous Cell Carcinoma, Chemoradiotherapy
Oral Microbiome is Associated With the Response to Chemoradiotherapy in Initial Inoperable Patients With Esophageal Squamous Cell Cancer
Esophageal cancer accounts for more than half of the world, seriously affecting people's health in China. 95% patients are squamous cell carcinoma.
- Conditions
- Esophageal Squamous Cell Carcinoma, Chemoradiotherapy, Initial Inoperable
- Trial name
- NCT06190847
- Testing
- regular chemoradiotherapy
- Where
- China
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- Anhui Provincial Hospital
Hepatocellular Carcinoma (HCC), Liver Neoplasms
Validation of Blood-Based Biomarkers in TACE-Treated Hepatocellular Carcinoma
The goal of this prospective observational study is to validate the clinical utility of specific blood-based biomarkers for predicting and monitoring treatment response in patients with hepatocellular carcinoma (HCC) undergoing…
- Trial name
- BLOOD-TACE-M (NCT07414433)
- Where
- Serbia
- Volunteers
- 60 people
- Sponsor
- University of Belgrade
Lymphoma, Multiple Myeloma
Immunologic Response After Pandemic Influenza A (H1N1) Vaccine in Onco- Hematologic Patients
Primary objective 1) To assess whether oncologic and hematologic patients develop a protective immunological response after pandemic Influenza A (H1N1) vaccine Secondary objectives 1.
- Conditions
- Lymphoma, Multiple Myeloma, Myeloproliferative Disease
- Trial name
- NCT01394640
- Testing
- Reassortant vaccine virus NYMC X-179A (New York Medical College, New York) derived form the A/california/7/2009 (H1N1) virus
- Where
- Italy
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Paolo Corradini
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer
By doing this study, the research team would like to learn if using a blood test that measures the amount of tumor DNA in blood can help guide how to use chemotherapy combined with immunotherapy for individuals with head and neck…
- Conditions
- Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Neoplasms, Head Cancer
- Trial name
- NCT05420948
- Testing
- Pembrolizumab, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Chicago
Multiple Myeloma
UARK 2015-03 A Phase II Trial of a Novel Proteasome/IMiD Combination
The purpose of this study is to determine the efficacy of Ixazomib when combined with Pomalidomide and Dexamethasone, in terms of overall response rate in subjects with relapsed Multiple Myeloma
- Trial name
- NCT02578121
- Testing
- Ixazomib, Pomalidomide, Dexamethasone
- Where
- United States
- Sponsor
- University of Arkansas
Hepatocellular Carcinoma (HCC), Treatment Response
Multimodalomics-based Construction of Spatiotemporal Characteristics of Dynamic Liver Cancer Microenvironment to Characterize the Clinical Application of Immune Mechanisms in Liver Cancer
This study aims to explore whether adding an additional MRI sequence to routine liver scans can better characterize the immune microenvironment of liver cancer.
- Trial name
- NCT07838415
- Testing
- time-dependent diffusion MRI and Cest sequence
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Tongji Hospital
Alzheimer Disease, Late Onset
The Predictive Factors of Good Clinical Response to Cholinesterase Inhibitors in Alzheimer Disease and Mixed Dementia
Background and objectives: The aims of this naturalistic study were: to analyze factors which could be predictive of good response to cholinesterase inhibitors (ChEI), such as: age, sex, schooling, mild (CDR 1) or moderate…
- Trial name
- NCT02187276
- Testing
- cholinesterase inhibitors
- Volunteers
- 129 people
- Sponsor
- Federal University of Minas Gerais
Myeloma
Treatment of Myeloma in Patients <= 65 Years Old With Response >= 50% After HSC Autotransplant by Allogenic Transplant Genoidentical or Phenoidentical After Reduced Intensity Conditioning
Donor mobilization : Donor will be mobilized with G-CSF (Granocyte) sub-cutaneous 10 µg/kg/day during 5 to 6 days. Hematopoïetic Stem Cell Harvest: By 1, 2, or 3 aphaeresis, a number of 4 x 106 cellules CD34+ /kg is required.
- Trial name
- IFM 2005-03 (NCT00466674)
- Testing
- reduced intensity conditioning
- Where
- France
- Volunteers
- 13 people
- Sponsor
- Hospices Civils de Lyon
Sarcoma
Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare Subtype
This is a randomized open label study, with 2 arms treatments conducted in patients with metastatic or unresectable advanced sarcoma of rare subtype; previously treated by anthracycline-based regimen except for whom standard…
- Trial name
- RAR-Immune (NCT04741438)
- Testing
- Nivolumab and IPILIMUMAB, Pazopanib Oral Tablet [Votrient]
- Where
- 13 sites in France
- Volunteers
- 96 people
- Sponsor
- Centre Leon Berard
Chronic Myeloid Leukemia, BCR-ABL1 Positive
Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia
This randomized phase IIB trial studies imatinib mesylate at two different doses and dasatinib to see how well they work in treating patients with previously untreated chronic phase chronic myelogenous leukemia.
- Trial name
- NCT00070499
- Testing
- Dasatinib, Imatinib Mesylate, Laboratory Biomarker Analysis
- Where
- 340 sites in United States, Canada
- Volunteers
- 406 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Renal Cell Carcinoma
A Retrospective Real World Analysis Of Sutent In Patients With Metastatic Renal Cell Carcinoma In Community And Academic Centers To Assess The Impact Of Dose Variation On Duration Of Response And Overall Survival
This is a retrospective, non-interventional study which looks at the cohort of Renal Cell Carcinoma patients in a real life clinical setting and analyses into factors why these patients have been surviving for as long as 3-5…
- Trial name
- NCT01917214
- Testing
- Sutent: Observational Study
- Volunteers
- 212 people
- Sponsor
- Pfizer
Multiple Myeloma, Post Allografting
IMMUNOPHENOTYPE ROLE IN THE EVALUATION OF CLINICAL RESPONSE
The study proposed by SSCVD Allogeneic Stem Cells of this Hospital provides for the collection of a series composed of patients with multiple myeloma undergoing allogeneic stem cell transplants at our center in the period…
- Trial name
- NCT02023671
- Volunteers
- 70 people
- Sponsor
- Azienda Ospedaliera San Giovanni Battista
Squamous Cell Carcinoma of the Head and Neck
Hemopurifier Plus Pembrolizumab in Head and Neck Cancer
This is an Early Feasibility Study (EFS) investigating the use of the Hemopurifier to clear immunosuppressive exosomes in combination with pembrolizumab (Keytruda) in the front line setting, in patients with advanced and/or…
- Trial name
- NCT04453046
- Testing
- Hemopurifier, Pembrolizumab 200mg IV
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Aethlon Medical Inc.
Plasma Cell Disorder
Disease Characteristics and Treatment Response in Plasma Cell Disorders Patients Based on Genetic Abnormalities From Fluorescence In Situ Hybridization and Next Generation Sequencing
The goal of this observational study is to study the genetic landscape in patients with Plasma Cell Disorders including MGUS, SMM, MM, and amyloidosis in Thailand.
- Trial name
- genetics MM (NCT06330896)
- Volunteers
- 498 people
- Sponsor
- Siriraj Hospital
Peripheral T Cell Lymphoma
T Cell Lymphoma -Stratified Therapy After Response to First-line Treatment-NR
This study is a multicenter, two-arm, prospective clinical trial, comprising two groups: the allogeneic hematopoietic stem cell transplantation group (Allo-HSCT) and the alternative salvage regimens.
- Trial name
- T-START-NR (NCT07470996)
- Testing
- Allogenic stem cell transplant (ASCT), Salvage Therapy
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Anaplastic Large Cell Lymphoma, ALK-Negative, Follicular Helper T-Cell Lymphoma
Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
This phase III trial compares the effect of high dose chemotherapy and the patients' own (autologous) stem cells to observation only in patients with peripheral T-cell lymphoma who achieved a complete response after initial…
- Conditions
- Anaplastic Large Cell Lymphoma, ALK-Negative, Follicular Helper T-Cell Lymphoma, Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type, Peripheral T-Cell Lymphoma, Not Otherwise Specified
- Trial name
- NCT06724237
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Best Practice, Biospecimen Collection
- Where
- 165 sites in United States, Mexico
- Volunteers
- 294 people
- Sponsor
- Eastern Cooperative Oncology Group
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.